Arrowhead to Present at Upcoming Scientific Conferences
PASADENA, Calif. — June 13, 2013 — Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that the company will present data on the Dynamic PolyConjugate™ (DPC) siRNA delivery system and the ARC-520 hepatitis B drug candidate at three upcoming scientific conferences.
Scheduled conference presentations in June include the following:
The 18th Annual Meeting of the RNA Society – Davos, Switzerland, June 14, 2013
A workshop presentation titled, “ Development of Dynamic Polyconjugates for tissue-targeted delivery of siRNA,” will be presented by Christine Wooddell, Ph.D., Senior Scientist;
4th RNAi Research & Therapeutics Conference – San Francisco, CA, USA, June 21, 2013
A featured presentation titled, “DPC Technology for siRNA Delivery: Moving from Platform to Pipeline” will be presented by David Lewis, Ph.D., Vice President, Biology;
The European CLINAM and ETPN Summit, Clinical Nanomedicine and Targeted Medicine – Basel, Switzerland, June 26, 2013
An oral presentation titled, “A Novel Hepatitis B Treatment with RNAi,” will be presented by Christopher Anzalone, Ph.D., President and CEO.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.
For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company’s email list to receive news directly, please send an email to ir@arrowres.com
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.